BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21648293)

  • 1. Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure.
    Kojori F; Cronin CM; Salamon E; Burym C; Sellers EA
    J Pediatr Endocrinol Metab; 2011; 24(3-4):203-4. PubMed ID: 21648293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
    Tripto-Shkolnik L; Blumenfeld Z; Bronshtein M; Salmon A; Jaffe A
    J Clin Endocrinol Metab; 2013 Feb; 98(2):443-7. PubMed ID: 23275528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
    Lecka A; Ginalska-Malinowska M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report.
    Baszko-Błaszyk D; Ochmańska K; Waśko R; Sowiński J
    Endokrynol Pol; 2011; 62(2):186-8. PubMed ID: 21528483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant mitotane in adrenocortical carcinoma.
    Dickstein G; Shechner C; Nativ O
    N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant mitotane in adrenocortical carcinoma.
    Lee JE
    N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant mitotane in adrenocortical carcinoma.
    Bertherat J; Coste J; Bertagna X
    N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mitotane in the treatment of adrenal carcinoma].
    Sane T
    Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant mitotane therapy of adrenal cancer - use and controversy.
    Schteingart DE
    N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
    Berruti A; Fassnacht M; Baudin E; Hammer G; Haak H; Leboulleux S; Skogseid B; Allolio B; Terzolo M
    J Clin Oncol; 2010 Aug; 28(23):e401-2; author reply e403. PubMed ID: 20567001
    [No Abstract]   [Full Text] [Related]  

  • 11. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
    Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
    Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectopic adrenocortical carcinoma of the ovary: An unexpected outcome.
    Salle L; Mas R; Teissier-Clément MP
    Ann Endocrinol (Paris); 2020 Oct; 81(5):516-518. PubMed ID: 32822651
    [No Abstract]   [Full Text] [Related]  

  • 13. Discussion.
    J Am Coll Surg; 2016 Apr; 222(4):490-2. PubMed ID: 27016977
    [No Abstract]   [Full Text] [Related]  

  • 14. The next generation of therapies for adrenocortical cancers.
    Kirschner LS
    Trends Endocrinol Metab; 2012 Jul; 23(7):343-50. PubMed ID: 22626690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
    Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
    Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma.
    De León DD; Lange BJ; Walterhouse D; Moshang T
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4452-6. PubMed ID: 12364417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Practical use of o,p'DDD in adrenocortical carcinoma].
    Bacchetta J; Droz JP
    Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
    Kerkhofs TM; Derijks LJ; Ettaieb H; den Hartigh J; Neef K; Gelderblom H; Guchelaar HJ; Haak HR
    Ther Drug Monit; 2015 Feb; 37(1):58-65. PubMed ID: 24887633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
    Demeure MJ; Somberg LB
    Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
    Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
    Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.